| Filed On | Filing |
|---|---|
| 20 Oct 2026 |
Form 4: Hoffman Robert E., Chief Executive Officer
Granted 2,500,000 Non-qualified stock option (right to buy) |
| 19 Oct 2026 | DEFA14A |
| 19 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
CYTODYN INVESTOR UPDATE WEBINAR THE WEBINAR WILL START SOON Participants Jacob Lalezari M.D. Chief Executive Officer of CytoDyn Robert E. Hoffman Chief Financial Officer of CytoDyn Medical Director of GI Oncology, City of Hope Orange Cou... |
| 14 Oct 2026 | 10-Q |
| 07 Oct 2026 | EFFECT |
| 07 Oct 2026 | 424B3 |
| 02 Oct 2026 | EFFECT |
| 02 Oct 2026 | EFFECT |
| 28 Sep 2026 |
Proxy statement: annual meeting on September 24, 2026
CEO pay $1.8M, up 134% · say-on-pay vote |
| 25 Sep 2026 | S-3 |
| 25 Sep 2026 | POS AM |
| 25 Sep 2026 | POS AM |
| 31 Aug 2026 | 10-K |
| 20 May 2026 | EFFECT |
| 20 May 2026 | 424B3 |
| 11 May 2026 | D |
| 30 Apr 2026 | 8-K: Regulation FD Disclosure |
| 22 Apr 2026 | S-1 |
| 08 Apr 2026 | 424B3 |
| 08 Apr 2026 | 10-Q |
Loading...
